References
- Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005;27:504-28. https://doi.org/10.1097/01.dad.0000181109.54532.c5
- Avcu G, Sensoy G, Celiksoy MH, Sogut A, Kefeli M, Karli A, et al. Cutaneous leukocytoclastic vasculitis associated with antituberculosis drugs. Pediatr Int 2015;57:155-7. https://doi.org/10.1111/ped.12403
- Kim JH, Moon JI, Kim JE, Choi GS, Park HS, Ye YM, et al. Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide. Allergy Asthma Immunol Res 2010;2:55-8. https://doi.org/10.4168/aair.2010.2.1.55
- Calabrese LH, Michel BA, Bloch DA, Arend WP, Edworthy SM, Fauci AS, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990;33:1108-13.
- Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936-41.
Cited by
- Ethambutol/isoniazid/rifampicin : Cutaneous leukocytoclastic vasculitis with gastrointestinal involvement: case report vol.1667, pp.1, 2017, https://doi.org/10.1007/s40278-017-35276-z